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1. Introduction
Relaxin is a member of the insulin superfamily of polypeptide
hormones [1]. The earliest characterized functions for relaxin
are in pregnancy, where it inhibits uterine contraction,
induces softening of the birth canal, and induces lengthening
of the interpubic ligament, largely by inducing extracellular
matrix remodeling [1,2]. Several studies have suggested that
relaxin may be effective in the treatment of conditions
characterized by excess collagen deposition, including pul-
monary, renal, and dermal fibrosis [3–5]. Furthermore, relaxin-
null mice were found to develop age-related fibrosis in the
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The polypeptide hormone relaxin has antifibrotic effects on a number of tissues, including
the liver. Central to the progression of hepatic fibrosis is the transdifferentiation of hepatic
stellate cells (HSC) from a quiescent state to an activated, myofibroblastic phenotype that
secretes fibrillar collagen. Relaxin inhibits markers of HSC activation, but relaxin receptor
expression in the liver is unclear. The purpose of this studywas to determine the expression
of the relaxin receptors LGR7 and LGR8 in activatedHSC. Production of cAMPwas induced by
treatment of HSC with relaxin, or the relaxin-related peptides InsL3 or relaxin-3, selective
activators of LGR8 and LGR7, respectively. Quiescent HSC expressed low levels of LGR7 but
not LGR8. During progression to the activated phenotype, expression of both receptors
increased markedly. Immunocytochemistry confirmed the presence of both receptors in
activated HSC. In normal rat liver, LGR7, but not LGR8, was expressed at low levels. In
cirrhotic liver, expression of both receptors significantly increased. Neither receptor was
detectable in normal liver by immunohistochemistry, but both LGR7 and LGR8 were readily
detectable in cirrhosis. These results were confirmed in human cirrhotic tissue, with the
additional finding of occasional perisinusoidal LGR7 immunoreactivity in non-cirrhotic
tissue. In conclusion, the expression of LGR7 and LGR8 is increased with activation of
HSC in culture. Cirrhosis also caused increased expression of both receptors. Therefore,
agents that stimulate LGR8 and LGR7may be therapeutically useful to limit the activation of
hepatic stellate cells in liver injury.
Published by Elsevier Inc.
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lung, kidney, heart, and skin [6–9]. Together, these findings
suggest that relaxinmay function as a protective agent against
fibrosis outside the reproductive system.
Hepatic fibrosis is characterized by excess deposition of
fibrillar collagen and other extracellularmatrix components in
the liver [10]. Central to this process is the activation of hepatic
stellate cells (HSC) from a quiescent, retinoid-storing state to a
myofibroblastic phenotype characterized by increased pro-
duction of collagen and other extracellular matrix compo-
nents, elevated proliferative rate, expression of a-smooth
muscle actin (SMA), and increased responsiveness to cyto-
kines [11,12]. Normally, HSC activation is an early event in the
healing process after liver injury, and upon removal of the
injurious stimulus there is a reduction of activated HSC, either
through apoptosis or through a return to the quiescent state.
Persistent injury results in sustained HSC activation, pro-
longedextracellularmatrix deposition, fibrosis, andultimately
cirrhosis. Therefore, the reduction or reversal of HSC activa-
tion is an attractive therapeutic target in the treatment of
hepatic fibrosis [10,13].
Relaxin also has effects in the liver. Relaxin treatment of
rats caused acute changes in hepatic microcirculation, and
induced morphological changes in sinusoidal myofibroblastic
cells [14]. In addition, the relaxin-null mouse developed
significantly increased liver weight [15], although it was not
reported if this phenomenon was due to increased collagen.
Relaxin has effects on liver cells, particularly HSC. Relaxin
treatment decreased collagen synthesis, total collagen content
and SMA protein level in HSC cultures [16,17]. Relaxin also
decreased the expression of tissue inhibitors of metallopro-
teinases (TIMPs) and increased the expression of the rodent
interstitial collagenase MMP-13 [16,17]. Finally, relaxin treat-
ment of experimentally induced hepatic fibrosis resulted in
decreased liver collagen [17], suggesting that relaxin treatment
may benefit hepatic fibrosis in vivo.
Althoughmany physiological functions of relaxin are being
identified, the relaxin receptors have only recently been
characterized at the molecular level. Two receptors, the
leucine-rich G-protein-coupled receptors LGR7 and LGR8 are
activated by relaxin [18]. Both are Gs-coupled receptors, and
therefore induce cAMP production through activation of
adenylyl cyclase [18]. While both receptors are activated by
relaxin, there is specificity in their response to other relaxin
family members. InsL3 (insulin-like peptide 3, also known as
relaxin-like factor and Leydig cell insulin-like peptide)
potently activates LGR8, but does not activate LGR7. A third
hormone, relaxin-3 (also known as insulin-like peptide 7) can
activate LGR7, but displays little activation of LGR8. Using
these tools, the present study sought to determine the
expression of the relaxin receptors in HSC and in diseased
liver tissue.
2. Materials and methods
Purified porcine relaxin was generously provided by Dr. O.
David Sherwood (University of Illinois at Urbana-Champaign),
or was purchased from the National Hormone & Peptide
Program (NIDDK). Human InsL3 and relaxin-3, and antibodies
to LGR7 and LGR8 were purchased from Phoenix Pharmaceu-
ticals (Belmont, CA). Nycodenz was purchased from Accurate
Chemical (Westbury, NY). Peroxidase-conjugated secondary
antibodieswere from Jackson Immunochemicals (West Grove,
PA). The antibodies directed against SMA and desmin were
from Sigma (St. Louis, CA).
2.1. Cell preparation and culture
Rat HSC were isolated from SAS–Sprague–Dawley rats (400–
500 g) using sequential perfusion with pronase and collage-
nase, followed by density gradient centrifugation in Nycodenz
as described previously [19]. Cell viability was monitored by
trypan blue exclusion, and HSC identified by their typical
morphology and the presence of fat droplets under UV
illumination. The HSC were maintained in DMEM/Ham’s F12
medium supplemented with 10% fetal bovine serum, 2 mM
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at
37 8C in a humidified 5% CO2 atmosphere. The medium was
changed 24 h after seeding and every 48 h thereafter. Within
7–10 days of culture, the HSC displayed the activated
(myofibroblastic) phenotype identified by the loss of lipid
droplets and the expression of SMA by immunoblotting or
immunocytochemistry. At 2 days (quiescent HSC) or 12 days
(activatedHSC) of growth, the cellswere used for experiments.
2.2. cAMP determination
HSC cultured for 2 days (quiescent) or 12 days (activated) were
seeded into 96-well plates (30,000 cells/cm2), and grown for
24 h. Cells were serum-deprived 16 h in DMEM/Ham’s F12
medium with 0.1% BSA, then treated for 30 min with 0.5 mM
isobutylmethyl xanthine (IBMX) to inhibit phosphodiesterase
activity. Relaxin (0.01–100 nM), InsL3 or relaxin-3 (1 nM) was
then added and cells were incubated for 30 min. Control cells
received IBMX treatment as above, then received medium
alone. Cells were lysed and intracellular cAMP concentrations
determined using the Biotrak EIA kit (Amersham, Piscataway,
NJ) according to the manufacturer’s instructions. Data were
normalized to the protein level in the lysates as determined by
the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL).
2.3. Real-time quantitative RT-PCR analysis of receptor
expression
Total RNA was extracted from whole rat liver or cultured HSC
using the PureLink system (Invitrogen, Carlsbad, CA). Reverse
transcription and quantitative PCR were performed using
TaqMan One-Step RT-PCR Master Mix (Applied Biosystems,
Foster City, CA). The TaqMan intron-spanning primers and
TAMRA-labeled probes sets usedwere Rn01495351_m1 (LGR7),
Rn01412901_m1 (LGR8), and Hs99999901_s1 (18S rRNA). The
expression level of LGR7 and LGR8were determined relative to
that of ribosomal 18S RNA using the comparative CT method.
The data are presented as the expression level relative to that
of LGR7 in control liver or quiescent HSC.
2.4. Immunocytochemistry
HSC were grown on 8-well glass chamber slides for 12 days
before use. Cells were fixed with 4% paraformaldehyde for
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10 min, washed in PBS (50 mM sodium phosphate, pH 7.4,
0.15 MNaCl) thenpermeabilized in 0.1%TritonX-100 in PBS for
10 min. Endogenous peroxidase activity was quenched by
incubation in 3% H2O2 in PBS for 5 min, and non-specific
binding was minimized by incubation in blocking buffer (3%
BSA, 0.1% Tween-20 in PBS) for 30 min. Cells were then probed
with monoclonal antibodies to SMA or desmin (1:400), or
polyclonal antibodies to LGR7 and LGR8 (1:200) in blocking
buffer for 1 h. Control cells were probed with appropriately
diluted non-immune mouse IgG or rabbit serum. Immunor-
eactive proteins were detected using the ABC system (Vector
Labs, Burlingame, CA), and visualized with DAB staining. Cells
were counterstained with hematoxylin, dehydrated, and
mounted.
2.5. Experimental liver disease
All procedures involving animals conformed to The Guide for
the Care and Use of Laboratory Animals, and were approved by
the Omaha VA Subcommittee of Animals Studies (IACUC).
Cirrhosis was induced in male Sprague–Dawley rats as
described previously [20]. Briefly, rats were fed standard chow
ad libitum and given water containing 1.5 mM phenobarbital
for 12weeks.When the rats reached approximately 200 g, CCl4
was administered weekly by intragastric gavage, with an
initial dose of 0.04 ml. Each subsequent dose of CCl4 was
adjusted in increments of 0.04 ml based on the percentage of
bodyweight gained or lostwithin 2 days of the previousweek’s
CCl4 treatment, according to the system devised by Proctor
and Chatamra [21]. Control rats received water containing
phenobarbital for the same period of time. At the end of
treatment, samples of the livers were removed, fixed in
formalin, and embedded in paraffin.
2.6. Immunohistochemistry
Sections of fixed, paraffin-embedded tissue from human
specimens of cirrhotic or non-cirrhotic liver tissue, or rat
liver as described above, were dewaxed, then subject to
antigen retrieval using Antigen Unmasking Solution (Vector
Labs, Burlingame, CA) and autoclaving for 15 min. After a
5 min 3% H2O2 for 5 min to quench endogenous peroxidases,
sections were blocked for 30 min blocking buffer. Sections
were probed with rabbit polyclonal antibodies to LGR7 and
LGR8 (1:200), or mouse monoclonal antibody to SMA (1:400),
diluted in blocking buffer. To assess background reactivity,
control slides were probed with appropriately diluted non-
immune rabbit serum or mouse IgG. Immunoreactive
proteins were detected using a biotin-fee system (EnVision,
Dako, Carpinteria, CA), and DAB staining. After counter-
staining with haematoxylin, the slides were dehydrated and
mounted.
2.7. Statistics
All data are expressed as mean  S.E. Comparisons for
differences between groups were made by ANOVA with
Tukey’s post-test. p < 0.05 was interpreted as significant.
Curve-fitting was performed using the Prism 4.0 software
package (GraphPad Inc., San Diego, CA).
3. Results
Previous studies showed that HSC respond to relaxin treat-
ment [16,17]. The two receptors activated by relaxin are LGR7
and LGR8, which are Gs-coupled receptors that induce cAMP
productionwhen activated by relaxin [18]. To determine if HSC
possess functioning relaxin receptors, activated cells were
treatedwith relaxin, and cAMPproductionwasmeasuredafter
30 min. Relaxin treatment induced a dose-dependent eleva-
tion in cAMP (Fig. 1). Themaximal increasewas approximately
three-fold, at 1 nM relaxin. To determinewhich receptorswere
present, selective agonists of relaxin receptors were used.
Insulin-like peptide 3 (InsL3), also knownas relaxin-like factor,
is a selective activator of LGR8 [22]. Another relaxin family
member, relaxin-3 (also known as InsL7), is a selective
activator of LGR7 [23]. Treatment of activated HSC with either
relaxin-3 or InsL3 significantly increased cellular cAMP to a
level comparable to that induced by relaxin (Fig. 2). In contrast,
treatment of quiescent cells resulted in no response to relaxin
or InsL3, and a small but statistically insignificant increase in
cAMP with relaxin-3 treatment. These data suggest that
activated HSC are sensitive to relaxin receptor agonists, but
that quiescent HSC have a reduced or absent response.
To determine examine relaxin receptor expression in HSC
during the progression to the activated phenotype, isolated
cells were cultured for 2 days (quiescent HSC) through 12 days
(activated HSC). The levels of the transcripts for LGR7 and
LGR8 were determined using quantitative real-time RT-PCR
using specific primer and probe sets. All values were normal-
ized to the level of 18S ribosomal RNA. In quiescent cells
(cultured for 2 days), a relatively low level of expression of
LGR7 was detected (Fig. 3). At day 4 the expression had
increased four-fold, and this level was maintained through
day 8. By days 10–12, a dramatic increase in LGR7 expression to
more than 30-fold of the day 2 level was detected. In contrast,
Fig. 1 – Elevation of cAMP levels by relaxin. Activated HSC
were serum-deprived overnight, then treated with 0.5 mM
IBMX for 30 min. Cells were treated with relaxin at the
indicated concentrations for 30 min. The concentration of
cAMP was determined using an EIA kit (Amersham). Data
are expressed as fmoles cAMP per mg total protein,
meanW S.E.M. for five determinations. *p < 0.001
compared with untreated cells.
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LGR8 expression was undetectable until day 8. From days 10–
12, a marked increase in LGR8 expression occurred, reaching a
level 60-fold higher than the initial level of LGR7. These
findings suggest that quiescent HSC express LGR7 at low
levels, but that transdifferentiation of HSC to the myofibro-
blastic phenotype is accompanied by a marked increase in
LGR7 and LGR8 expression.
To examine the expression of LGR7 and LGR8 proteins in
HSC, activated cells were fixed and examined by immunocy-
tochemistry for the presence of LGR7, LGR8, SMA, or desmin
(Fig. 4). The cells showed positive staining for LGR7 and LGR8
compared to non-immune rabbit serum. As expected, SMA
was readily detectable,while desmin expressionwas absent in
Fig. 2 – Relaxin family peptides induce cAMP production in
HSC. Quiescent or activated HSC were serum-deprived
overnight, then treated with 0.5 mM IBMX for 30 min. Cells
were then treated with 1 nM relaxin, InsL3 or relaxin-3 for
30 min. The concentration of cAMP was determined using
an EIA kit (Amersham). Data are expressed as fmoles
cAMP per mg total protein, meanW S.E.M. for three
determinations. *p < 0.05 compared to untreated
cells.
Fig. 3 – Relaxin receptor expression in HSC. Expression of
LGR7 or LGR8 was determined by real-time TaqMan RT-
PCR analysis of RNA from primary rat HSC. Cells were
cultured for 2 days (quiescent) or up to 12 days (activated).
Total RNA was analyzed by TaqMan using validated
primer/probe sets for LGR7, LGR8, or 18S ribosomal RNA as
an internal standard. Expression levels are relative to that
of LGR7 transcript at 2 days. Data are from three
independent experiments.
Fig. 4 – Immunocytochemical detection of LGRs in activated HSC. Primary HSC were cultured for 12 days, then were analyzed
by immunocytochemistry using rabbit polyclonal antibodies directed against LGR7 or LGR8, or mouse monoclonal
antibodies directed against SMA or desmin. Control cells were probed with non-immune rabbit serum or mouse IgG at the
same dilution. Immunoreactive proteins were detected with peroxidase-conjugated secondary antibodies and DAB.
Original magnification: 100T.
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the majority of cells, verifying the activated HSC phenotype
[24]. Non-immune mouse IgG produced no positive signal.
These data confirm at the protein level the gene expression
data demonstrating that LGR7 and LGR8 are expressed by
activated HSC.
Hepatic fibrosis is characterized by the transdifferentiation
of HSC to the activated, myofibroblastic phenotype. To
determine if relaxin receptor expression is increased in
activated HSC in vivo, a rodent model of cirrhosis was used.
Rats were treated for 12 weeks with CCl4 to induce cirrhosis,
the total liver RNA was extracted and analyzed for LGR7 and
LGR8 expression by quantitative real-time RT-PCR (Fig. 5). In
control liver, a low level of LGR7 expression was detected. In
three of four control liver specimens, LGR8 expression was
completely undetectable. In contrast, cirrhotic livers had
significantly elevated levels of both LGR7 and LGR8 transcripts.
These datamirror the results using isolatedHSC suggesting an
induction of relaxin receptor expression with HSC activation.
To confirm the gene expression results at the protein level,
fixed paraffin-embedded sections of control and cirrhotic rat
liver were analyzed by immunohistochemistry for presence of
for LGR7, LGR8, or SMA (Fig. 6). No immunoreactivity against
LGR7 or LGR8 was detectable in normal tissue. In cirrhotic
tissue, LGR7 and LGR8 immunoreactivity was readily detect-
able, predominantly at the outer edge of the fibrotic septae
adjacent to hepatocytes. For comparison, SMA immunoreac-
tivity was limited to vascular smooth muscle cells in control
liver, but present in perivenular areas and in and around the
fibrotic septae in cirrhotic tissue. Taken together, these data
support the gene expression data showing increased LGR7 and
LGR8 expression in diseased liver. The localization of relaxin
receptors in diseased liverwas similar, but not identical, to the
pattern seen for SMA. Finally, similar results were obtained
using human liver (Fig. 7). In cirrhotic tissue, both LGR7 and
LGR8 immunoreactivity was detected in and around the
fibrotic scar. No LGR8 immunoreactivity was detectable in
non-cirrhotic tissue. However, some perisinusoidal cells did
show positive immunoreactivity toward LGR7 in non-cirrhotic
tissue (inset).
4. Discussion
Previous studies had demonstrated antifibrotic effects of
relaxin on HSC. In addition to a decrease in total collagen
levels, the rate of new collagen synthesis was reduced, and the
level of type I collagen was decreased [16,17]. The level of the
matrix metalloproteinase MMP13 was increased, while the
levels of the tissue inhibitors ofmetalloproteinases TIMP1 and
TIMP2 were decreased, suggesting that relaxin induces a
matrix degrading phenotype in activated HSC [16,17]. In
addition, the level of SMAwas reduced with relaxin exposure,
raising the possibility that relaxin may have effects on portal
hypertension [16]. Finally, relaxin treatment of experimental
hepatic fibrosis resulted in a decrease in liver collagen content
[17]. While these studies inferred the presence of receptors in
the liver, the lack of identification of a distinct cognate
receptor hampered the study of relaxin receptors in the liver.
The identification of the relaxin receptors LGR7 and LGR8 [18]
now allows those studies to be performed.
Treatment with relaxin-3 or InsL3, selective activators of
LGR7 and LGR8, respectively, induced cAMP production to the
same level as relaxin, which activates both receptors. This is
possibly due to the fact that relaxin has approximately three-
fold lower affinity for LGR8 than LGR7 [18]. However, some
caution should be used with interpretation of these data. As
discussed earlier, porcine relaxin activates both LGR7 and
LGR8 from human, rat or mouse sources. But recent evidence
suggests thatmouse or rat relaxin activates only LGR7 in these
species [25]. This was further illustrated by the inability of
mouse relaxin to rescue the failed testicular descent in the
InsL3-null mouse [26], and thus in the rodent, InsL3 alone is
responsible for activation of LGR8. One study has suggested
that human relaxin-3may activate rat LGR8 [25], and therefore
it is possible that the increased cAMP in HSC exposed to
porcine relaxin, or human InsL3 and relaxin-3, may be due to
activation of LGR8.
Two additional receptors for relaxin-3 have been identified,
known as GPCR135 (RXFP3) and GPCR142 (RXFP4) [27,28].
Neither of these receptors is activated by relaxin or InsL3.
GPCR142 is a pseudogene in rats, and therefore is uninvolved
in our studies. Furthermore, both GPCR135 and GPCR142 are
coupled to Gi, and therefore decrease cAMP production.
Therefore, our data suggest that, in HSC, LGR7 and LGR8 are
the receptors responsible for the increase in cAMP in response
to relaxin receptor agonists.
The expression of both relaxin receptors was detectable in
culture activated HSC, at both the mRNA and protein levels.
The presence of the receptors provides ameans for the relaxin
effects previously seen in HSC. Relaxin induced an increase in
the cAMP levels in these cells, consistent with activation of a
Gs-coupled receptor pathway. Interestingly, increased cAMP
has been implicated in the inhibition of markers of HSC
activation. Treatment of HSC with stable analogues of cAMP,
or agents that inhibit phosphodiesterases, resulted in reten-
tion of retinoid stores, suppressed SMA expression, decreased
Fig. 5 – Relaxin receptor expression in normal or cirrhotic
rat tissue. Rats were treated or not for 12 weeks with
carbon tetrachloride to induce cirrhosis. Total RNA
extracted from liver was probed for LGR7 or LGR8 by
TaqMan real-time RT-PCR using 18S RNA as an internal
control. All data shown are relative to the level of LGR7 in
normal liver. *p < 0.05 compared to normal, n = 4.
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proliferation, reduced collagen expression, and blunted
sensitivity to endothelin-1 [29–33]. Therefore, cAMP elevation
may be the mechanism of action for relaxin in these cells.
Previous studies examining hepatic expression of LGRs
have been inconsistent. Using total RNA from liver, transcripts
for LGR7 and LGR8 were either undetectable [34], or LGR7 only
was detected [35,36]. However, it should be noted that in both
of these cases, normal (non-diseased) liver was the source of
the analyzed samples. The results of the present study suggest
that only LGR7 is expressed in normal tissue, but expression of
Fig. 6 – Immunohistochemical detection of relaxin receptors in cirrhotic rat liver. Rats were treated with carbon tetrachloride
for 12 weeks to induce cirrhosis, and then probed with rabbit polyclonal antibodies to LGR7 or LGR8, or a mousemonoclonal
antibody to SMA, as described in Section 2. Control sections were probed with non-immune rabbit serum or mouse IgG at
the same protein level. Immunoreactive proteins were detected by peroxidase-conjugated secondary antibodies and DAB
staining. Original magnification: 100T.
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both LGR8 and LGR7 is upregulated with HSC activation. The
presence of relaxin receptors was detected in liver tissue from
diseased animals, but not in control animals. Despite the
findings of LGR7 transcript and protein in quiescent HSC, no
LGR7 immunoreactivity was detectable in control (non-
cirrhotic) liver in the rat. However, LGR7 immunoreactivity
was detected in perisinusoidal cells in non-cirrhotic human
tissue, consistent with quiescent HSC, but this finding was
relatively rare. This may be due to the low level of LGR7
expression in quiescent cells that was revealed in the gene
expression studies. Alternatively, it is possible that the
extraction of HSC and culture for 2 days produces the
induction of LGR7 expression in culture that is not reflected
in quiescent HSC in vivo.
The receptors were localized to the same areas that were
SMA positive, suggesting that they may be expressed in HSC.
However, the pattern of expression was not identical to SMA,
and may reflect a subset of HSC. Therefore, it may be that, in
vivo, the receptors are expressed only after the HSC have
become activated and have begun to participate in the healing
process. The relaxin receptors may then be involved in
inhibiting the sustained activation of HSC during the resolu-
tion processwherematrix production slows and excessmatrix
deposition is cleared. Further studies are needed to examine
the temporal expression of LGR7 and LGR8 during disease
progression and resolution.
Few studies have been performed examining the effects of
relaxin treatment on the liver in vivo. As discussed earlier,
relaxin treatment reduced the effects of carbon tetrachloride-
induced fibrosis [17]. Interestingly, effects of relaxin have been
detected in normal (undiseased) liver. Porcine relaxin treat-
ment causedmorphological changes in rat perisinusoidal liver
cells, and dilation of the sinusoids [14]. Relaxin had protective
effects against ischemia and reperfusion damage in perfused
rat liver [37]. In a recent study, 20-fold overexpression of
mouse relaxin for 4 months in a transgenic mouse model
resulted in increased liverweight and hydroxyproline inmales
but not females [26]. Because mouse relaxin does not activate
LGR8, and because our data suggests that only a low level of
LGR7 is expressed in non-fibrotic liver, these effects would
presumably be mediated by LGR7 alone. In addition, because
the phenomenon was observed in males only, additional
gender-specific factors are involved in the relaxin response.
Clearly, further studies are needed to identify the roles that
LGR7 and LGR8 each play in the regulation of collagen
production in the liver.
In summary, this is the first report of relaxin receptor
expression in liver cells. These findings were supported by the
detection of relaxin family peptide receptor expression in
diseased liver tissue. These studies expand the earlier studies
reporting effects of relaxin on HSC and experimental liver
disease, and raise the possibility that InsL3 or relaxin-3may be
additional agents useful in the treatment of chronic liver
injury.
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